Galectin-1 Inhibition as a Strategy for Malignant Peripheral Nerve Sheath Tumor Treatment

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Neurofibromatosis type 1 (NF1) predisposes individuals to malignant peripheral nerve sheath tumors (MPNSTs), an aggressive cancer with poor prognosis.
• Current MPNST treatments are limited, necessitating novel therapeutic approaches.
• The interaction between Galectin-1 and Ras signaling is implicated in MPNST progression.

Purpose of the Study:

• To investigate targeting the Galectin-1/Ras interaction as a novel therapeutic strategy for MPNSTs.
• To evaluate the efficacy of a novel compound, LLS30, designed to disrupt this interaction.

Main Methods:

• Molecular docking to identify key residues in the Galectin-1/H-Ras interaction.
• Synthesis and in vitro testing of LLS30 for its ability to disrupt Galectin-1/Ras binding.
• Assessment of LLS30's effects on MPNST cell proliferation, apoptosis, and Ras signaling.
• In vivo studies in animal models to evaluate anti-tumor efficacy, metastasis inhibition, and survival.
• Transcriptome analysis to elucidate molecular mechanisms of action.

Main Results:

• LLS30 successfully disrupted the Galectin-1/Ras interaction, leading to Ras delocalization and inhibited signaling.
• In vitro, LLS30 significantly reduced MPNST cell proliferation and induced apoptosis.
• In vivo, LLS30 demonstrated potent anti-tumor activity, reduced metastasis, and improved survival in animal models.
• Transcriptome analysis revealed downregulation of KRAS signaling and epithelial-mesenchymal transition pathways.

Conclusions:

• Targeting the Galectin-1/Ras interaction with LLS30 represents a promising therapeutic strategy for MPNSTs.
• LLS30 exhibits significant anti-tumor efficacy in both in vitro and in vivo models.
• This approach may also be beneficial for other cancers driven by Galectin-1 and Ras signaling.